XML 63 R37.htm IDEA: XBRL DOCUMENT v3.22.4
Research Collaboration and License Agreements - Additional Information (Details)
 1 Months Ended 4 Months Ended 12 Months Ended 43 Months Ended
Sep. 30, 2021
USD ($)
$ / shares
shares
Jul. 31, 2021
USD ($)
Dec. 31, 2020
USD ($)
$ / shares
shares
Nov. 30, 2017
USD ($)
Target
Dec. 31, 2015
USD ($)
Dec. 31, 2022
USD ($)
Dec. 31, 2021
USD ($)
shares
Dec. 31, 2020
USD ($)
$ / shares
shares
Dec. 31, 2018
USD ($)
Dec. 31, 2022
USD ($)
Dec. 31, 2023
USD ($)
Jun. 30, 2019
USD ($)
Research Collaboration And License Agreements [Line Items]                        
Contract revenue receivable if milestones achieved     $ 0     $ 10,700,000 $ 12,500,000 $ 0   $ 10,700,000    
Gross proceeds             259,900,000 431,900,000        
Collaboration contract asset and other assets           10,800,000 12,500,000     10,800,000    
Revenue adjustments arising from contract modifications           700,000 (800,000) (400,000)        
Accounts receivable     $ 1,000,000.0     1,000,000.0 $ 15,000,000.0 $ 1,000,000.0   1,000,000.0    
Common Shares                        
Research Collaboration And License Agreements [Line Items]                        
Issuances of common stock, net (in shares) | shares     6,571,428       3,500,000 6,600,000        
Share price, issued and sold (in usd per share) | $ / shares     $ 70.00         $ 70.00        
Pfizer, Inc.                        
Research Collaboration And License Agreements [Line Items]                        
Payments received             $ 1,200,000 $ 4,400,000 $ 28,000,000      
Pfizer, Inc. | Collaboration Agreement                        
Research Collaboration And License Agreements [Line Items]                        
Contract revenue receivable if milestones achieved   $ 650,000,000                    
Collaboration agreement direct and incremental costs incurred           12,900,000            
Collaboration contract asset and other assets           12,900,000       12,900,000    
Pfizer, Inc. | Stock Purchase Agreement                        
Research Collaboration And License Agreements [Line Items]                        
Contract revenue receivable if milestones achieved   650,000,000.0                    
Fair value of the shares sold   $ 85,400,000                    
Pfizer, Inc. | Stock Purchase Agreement | Common Shares                        
Research Collaboration And License Agreements [Line Items]                        
Issuances of common stock, net (in shares) | shares 3,457,815                      
Share price, issued and sold (in usd per share) | $ / shares $ 101.22                      
Gross proceeds $ 350,000,000.0                      
Financial advisor fees $ 4,600,000                      
Pfizer, Inc. | Development Milestone Payments | Maximum                        
Research Collaboration And License Agreements [Line Items]                        
Contract revenue receivable if milestones achieved           225,000,000       225,000,000    
Pfizer, Inc. | Sales-based Milestone Payments                        
Research Collaboration And License Agreements [Line Items]                        
Contract revenue receivable if milestones achieved           1,000,000,000       1,000,000,000    
Payments received           0            
Pfizer, Inc. | Sales-based Milestone Payments | Maximum                        
Research Collaboration And License Agreements [Line Items]                        
Contract revenue receivable if milestones achieved           550,000,000       550,000,000    
Pfizer, Inc. | Option Payments | Maximum                        
Research Collaboration And License Agreements [Line Items]                        
Contract revenue receivable if milestones achieved           37,500,000       37,500,000    
Pfizer, Inc. | Additional Target and Services                        
Research Collaboration And License Agreements [Line Items]                        
Accounts receivable           1,000,000 3,500,000     1,000,000    
Pfizer, Inc. | Regulatory Milestone Payments                        
Research Collaboration And License Agreements [Line Items]                        
Contract revenue receivable if milestones achieved           400,000,000       400,000,000    
Pfizer, Inc. | Regulatory Milestone Payments | Maximum                        
Research Collaboration And License Agreements [Line Items]                        
Contract revenue receivable if milestones achieved           1,400,000,000       1,400,000,000    
Bayer A G                        
Research Collaboration And License Agreements [Line Items]                        
Contract revenue receivable if milestones achieved                       $ 17,500,000
Bayer A G | Stock Purchase Agreement                        
Research Collaboration And License Agreements [Line Items]                        
Fair value of the shares sold           2,900,000            
Additional consideration received           2,900,000            
Bayer A G | Research Funding Payments                        
Research Collaboration And License Agreements [Line Items]                        
Contract revenue receivable if milestones achieved     $ 3,000,000     3,000,000 $ 3,000,000 $ 3,000,000   3,000,000    
Payments received                   10,500,000    
Bayer A G | Research Funding Payments | Scenario Forecast                        
Research Collaboration And License Agreements [Line Items]                        
Contract revenue receivable if milestones achieved                     $ 12,000,000  
Bayer A G | Development Milestone Payments                        
Research Collaboration And License Agreements [Line Items]                        
Payments received           0            
Bayer A G | Development Milestone Payments | Maximum                        
Research Collaboration And License Agreements [Line Items]                        
Contract revenue receivable if milestones achieved                       197,500,000
Bayer A G | Sales-based Milestone Payments                        
Research Collaboration And License Agreements [Line Items]                        
Payments received           0            
Bayer A G | Sales-based Milestone Payments | Maximum                        
Research Collaboration And License Agreements [Line Items]                        
Contract revenue receivable if milestones achieved                       $ 490,000,000
Genentech, Inc. and F. Hoffman-La Roche Ltd.                        
Research Collaboration And License Agreements [Line Items]                        
Payments received       $ 34,500,000 $ 11,000,000              
Number of designated targets | Target       10                
Genentech, Inc. and F. Hoffman-La Roche Ltd. | Development Milestone Payments                        
Research Collaboration And License Agreements [Line Items]                        
Payments received           0            
Genentech, Inc. and F. Hoffman-La Roche Ltd. | Development Milestone Payments | Maximum                        
Research Collaboration And License Agreements [Line Items]                        
Contract revenue receivable if milestones achieved           44,000,000       44,000,000    
Genentech, Inc. and F. Hoffman-La Roche Ltd. | Option Payments | Maximum                        
Research Collaboration And License Agreements [Line Items]                        
Contract revenue receivable if milestones achieved           27,500,000       27,500,000    
Genentech, Inc. and F. Hoffman-La Roche Ltd. | Regulatory Milestone Payments                        
Research Collaboration And License Agreements [Line Items]                        
Contract revenue receivable if milestones achieved           52,500,000       52,500,000    
Payments received           0            
Genentech, Inc. and F. Hoffman-La Roche Ltd. | Commercial Milestones                        
Research Collaboration And License Agreements [Line Items]                        
Contract revenue receivable if milestones achieved           60,000,000       $ 60,000,000    
Payments received           $ 0